Atara Biotherapeutics
ATRA
71 hedge funds and large institutions have $377M invested in Atara Biotherapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 19 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
16% less funds holding
Funds holding: 85 → 71 (-14)
26% less capital invested
Capital invested by funds: $509M → $377M (-$132M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
74% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$13.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.75M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$3.11M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.04M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$999K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.03M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.54M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.51M |
| 4 |
Morgan Stanley
New York
|
-$2.16M |
| 5 |
VAM
Visium Asset Management
New York
|
-$2.1M |
ATRA Hedge Fund Activity: Q1 2016 in Review
71 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2016, worth a combined $377M — down 26% from $509M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ATRA and 5 opened new positions — a net loss of 14 holders — while 17 trimmed existing stakes and 30 added.
The largest buyer was Redmile Group, adding an estimated $13.3M. The largest seller was State Street, cutting an estimated $6.03M.
- 71 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2016, down from 85 in Q4 2015.
- Funds reported $377M of Atara Biotherapeutics stock for Q1 2016, down 26% quarter-over-quarter.
- 5 funds opened new Atara Biotherapeutics positions in Q1 2016 and 19 closed out, a net change of -14 holders.
- The largest Atara Biotherapeutics buyer in Q1 2016 was Redmile Group, an estimated $13.3M added.
- The largest Atara Biotherapeutics seller in Q1 2016 was State Street, an estimated $6.03M sold.
Based on aggregated 13F filings for Q1 2016.